https://www.cochrane.org/evidence/CD004763_laser-photocoagulation-treating-neovascular-age-related-macular-degeneration
Laser photocoagulation for treating neovascular age-related macular degeneration | Cochrane
laser photocoagulationage relatedmacular degenerationtreatingneovascular
https://www.slideserve.com/geoffrey/current-controversies-in-the-management-of-neovascular-age-related-macular-degeneration
PPT - Current Controversies in the Management of Neovascular Age-Related Macular Degeneration...
Current Controversies in the Management of Neovascular Age-Related Macular Degeneration. Anthony B. Daniels, MD, MSc. Massachusetts Eye and Ear Infirmary,...
current controversiesin the
https://www.jci.org/assets/374641/powerpoint
JCI - Aqueous proteins help predict the response of patients with neovascular age-related macular...
https://www.cochrane.org/evidence/CD011230_systemic-whole-body-safety-bevacizumab-versus-ranibizumab-neovascular-age-related-macular
Systemic (whole body) safety of bevacizumab versus ranibizumab for neovascular age-related macular...
https://pmc.ncbi.nlm.nih.gov/articles/PMC2680096/
Triple therapy for neovascular age-related macular degeneration using single-session photodynamic...
To evaluate the efficacy and safety of triple therapy consisting single-session photodynamic therapy (PDT), intravitreal bevacizumab (IVB) and intravitreal...
triple therapyage related
https://www.jci.org/assets/374646/powerpoint
JCI - Aqueous proteins help predict the response of patients with neovascular age-related macular...
https://www.cochrane.org/evidence/CD012208_comparing-different-injection-frequencies-neovascular-age-related-macular-degeneration
Comparing different injection frequencies for neovascular age-related macular degeneration |...
age relatedcomparingdifferentinjectionfrequencies
https://www.mdpi.com/2077-0383/13/3/867
Two-Year Follow-Up Study of Patients with Neovascular Age-Related Macular Degeneration Undergoing...
Background: regular intravitreal anti-vascular endothelial growth factor (VEGF) treatment is crucial for patients with neovascular age-related macular...
https://www.marketscreener.com/news/merck-starts-phase-2b-3-trial-of-neovascular-age-related-macular-degeneration-treatment-ce7e51dcd180f523
Merck Starts Phase 2b/3 Trial of Neovascular Age-Related Macular Degeneration Treatment |...
Apr 2, 2026 - Merck said Thursday it launched a phase 2b/3 trial of MK-8748 to treat neovascular age-related macular degeneration, the most common cause of vision loss among...
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/neovascular-age-related-macular-degeneration-developing-drugs-treatment
Neovascular Age-Related Macular Degeneration: Developing Drugs for Treatment | FDA
Neovascular Age-Related Macular Degeneration: Developing Drugs for Treatment; Draft Guidance for Industry; Availability
age relatedmacular degenerationfor treatmentneovasculardeveloping
https://www.cochrane.org/es/evidence/CD005139_anti-vascular-endothelial-growth-factor-neovascular-age-related-macular-degeneration
Tratamiento anti-factor de crecimiento endotelial vascular para el glaucoma neovascular | Cochrane
de crecimiento
https://www.ncbi.nlm.nih.gov/books/NBK576393/
Neovascular Glaucoma - StatPearls - NCBI Bookshelf
Neovascular glaucoma (NVG) is a secondary glaucoma characterized by new vessels on the iris and angle of the anterior chamber (AC). It is usually associated...
neovascular glaucomastatpearlsncbibookshelf
https://pmc.ncbi.nlm.nih.gov/articles/PMC12505566/
Real-world short-term outcomes after switching to fixed-interval anti-VEGF therapy for neovascular...
To assess short-term real-world visual and anatomic outcomes in patients with neovascular age-related macular degeneration (nvAMD) following a protocol shift...
https://www.elsevier.es/en-revista-archivos-sociedad-espanola-oftalmologia-english-496-articulo-surprising-complete-regression-choroidal-neovascular-S2173579425000386
Surprising complete regression of a choroidal neovascular membrane with faricimab | Archivos de la...
Retinography of nAMD before and after treatment (Fig. 1A). Active type 1 CNV is observed in structural OCT and OCTA (Fig. 1B). Treatment is initiated
https://pmc.ncbi.nlm.nih.gov/articles/PMC5667400/
Effects of Aflibercept for Neovascular Age-Related Macular Degeneration: A Systematic Review and...
To compare the effects of aflibercept and other anti-vascular endothelial growth factor (anti-VEGF) medications on both functional and anatomical outcomes for...
https://pmc.ncbi.nlm.nih.gov/articles/PMC9666309/
Relationship between retinal fluid characteristics and vision in neovascular age-related macular...
To evaluate the relationship between retinal fluid location, amount/severity, and vision with ranibizumab-treated neovascular age-related macular degeneration...
https://pmc.ncbi.nlm.nih.gov/articles/PMC9654543/
A Linkage between Angiogenesis and Inflammation in Neovascular Age-Related Macular Degeneration -...
Age-related macular degeneration (AMD) is the leading cause of visual impairment in the aging population with a limited understanding of its pathogenesis and...
https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2018.00125/full
Frontiers | Outcome of 5-Year Treatment of Neovascular Age-Related Macular Degeneration With...
Objective: The aim of this study is two-fold. First, to evaluate the long-term outcome of anti-vascular endothelial growth factor (anti-VEGF) treatment in a...
of 5